go-v.orgdoi

Agalsidase alfa for the treatment of fabry disease: a closer look

Shawn E. Lipinski, Edina Komlódi-Pásztor, Özlem Göker-Alpan · Clinical Investigation · 2014

  • DOI 10.4155/cli.14.35
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2014

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2014

Abstract

Enzyme replacement therapies substitute particular enzymes in individuals who have deficient or absent levels of enzymatic activity due to inherited defects. Fabry disease, a rare X-linked genetic disorder yet common lysosomal storage disease, is due to the impaired activity of α-galactosidase A. Currently, there are two enzyme preparations available for the treatment of Fabry disease: agalsidase alfa (Replagal®), manufactured by Shire, and agalsidase beta (Fabrazyme®), manufactured by Genzyme. Here, we review the molecular characteristics and intracellular trafficking of the endogenous and exogenous enzymes as well as the pharmacological properties of Replagal.

We also summarize clinical experiences with Replagal and provide insight into its therapeutic value for the treatment of Fabry disease.

Open the resolved locator · 10.4155/cli.14.35

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 00:54 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.14.35
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.